Your browser doesn't support javascript.
loading
Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies.
Lalle, Eleonora; Mazzotta, Valentina; Sberna, Giuseppe; Fabeni, Lavinia; Garbuglia, Anna Rosa; Mastrorosa, Ilaria; D'Abramo, Alessandra; Nicastri, Emanuele; Girardi, Enrico; Antinori, Andrea; Maggi, Fabrizio; Bordi, Licia.
Afiliación
  • Lalle E; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Mazzotta V; Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Sberna G; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Fabeni L; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Garbuglia AR; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Mastrorosa I; Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • D'Abramo A; Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Nicastri E; Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Girardi E; Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Antinori A; Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Maggi F; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Bordi L; Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
Viruses ; 16(7)2024 Jun 27.
Article en En | MEDLINE | ID: mdl-39066203
ABSTRACT
Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Saliva / Nasofaringe / Sensibilidad y Especificidad / Ritonavir / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Saliva / Nasofaringe / Sensibilidad y Especificidad / Ritonavir / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Viruses Año: 2024 Tipo del documento: Article País de afiliación: Italia